Q3-26 (reported 10/13) was excellent and that is exactly the problem. EPS $17.01 vs $13.05 consensus, net revenue $18.7B (second-best ever), record Equities ($6.4B) on record prime/financing, IB fees $3.2B, AWM management fees a record $3.6B, AUS a record $4.10T with $97B of long-term inflows. Annualized ROE 18.7% (19.8% ex the $450M charitable gift); YTD 20.7%. The stock still fell — because at 2.34x book / 2.55x tangible, the market is already capitalizing a 20%+ ROE as permanent.
Normalize and the gap is wide. Goldman's 10-year reported ROE averages 11.7%; stripping TCJA, 1MDB and the Marcus exit lifts it to 12.9%; management's own through-the-cycle target is "mid-teens." Give them the full 15% — above the 10-yr record — at a 10.7% cost of equity and 3% growth, and the excess-return model, the Gordon/total-payout model and a sum-of-the-parts all land in the same $580–$625 neighbourhood. Even the bull case (18% ROE sustained, i.e. 2024–26 forever) is $771 — below today's price.
Reverse it: at $870 the stock requires a ~20.6% ROE in perpetuity, or — if you accept 15% — a cost of equity of ~8.5%, below where the 10Y Treasury plus any sane equity premium sits with Rf at 5.2%. On normalized payout the forward shareholder return is ~8.1% vs a 10.7% hurdle. You are being paid less than your cost of capital to own the peak of the cycle.
What the bulls get right (and why it's in the price): the mix shift is real — AWM is now ~25–29% of revenue with a 30% pre-tax margin target, $3.6B/qtr of sticky fees, alternatives at $491B AUS and a $750B 2030 target; consumer drag (Apple Card) is nearly gone. That is why base uses 15%, not the 12.3% raw average. But 71–74% of revenue is still GBM, and Equities/FICC/IB are running at record levels on a leverage- and financing-driven tape. Capital is also tighter than it looks: standardized CET1 fell to 12.4% from 14.4% at YE25 against an 11.4% requirement (SCB 3.4% locked through 9/30/27) — only ~100bp of headroom to keep funding $3B/qtr of buybacks.
Call: No new money above ~$700. Trim into strength; $771 (bull) is the ceiling of what fundamentals can defend. Accumulate below ~$620 (base), get aggressive below ~$520 (bear + margin). Holders who won't sell: overwrite — 30–45 DTE calls ~8–10% OTM (≈$950), or for a defined-risk bear view a bear call spread with the short strike ≥$960, well under the $1,154 July high, after post-earnings IV crush. Don't short outright: a capital-markets boom can carry ROE above 20% for several more quarters. Next print ~Jan 19, 2027.
| HIGH | Capital-markets cyclicality — ~74% of 9M26 revenue is GBM. Long: deal/IPO volumes, trading volatility, prime balances. Short: a risk-off reversal; 2022–23 ROE fell to 7.5–10% from 23%. |
| HIGH | Multiple compression — at 2.34x book, a de-rating to 1.6x (where 15% ROE justifies) is −33% with zero earnings miss. Short: rates (Rf 5.2%, Fed hiking bias raises COE). |
| MED | Capital headroom — CET1 12.4% vs 11.4% required; SLR 4.3%. Balance-sheet growth in financing is eating buyback capacity. Long: Basel endgame / eSLR relief. |
| MED | Principal investments & alts marks — on-balance-sheet PE/CRE (2023 writedowns) and incentive fees ($587M in Q3) are mark-to-market. Short: private-credit / PE valuation reset. |
| LOW | Credit — provisions $368M in Q3 ($785M YTD) on a mostly wholesale, collateralized book; Apple Card held for sale. |
| Normalized ROE ↓ / CoE → | 9.5% | 10.1% | 10.7% | 11.3% | 11.9% |
| 12.0% | $577 | $529 | $489 | $454 | $424 |
| 13.5% | $658 | $602 | $555 | $515 | $480 |
| 15.0% | $739 | $675 | $622 | $576 | $536 |
| 16.5% | $820 | $748 | $688 | $637 | $592 |
| 18.0% | $901 | $822 | $755 | $698 | $648 |
| 20.0% | $1,009 | $919 | $843 | $779 | $723 |
| Year | Net rev $B | NI to common $M | Dil. EPS | Reported ROE | Adj. ROE | One-offs |
| 2016 | 30.6 | 7,087 | 16.29 | 9.4% | 9.4% | |
| 2017 | 32.1 | 3,685 | 9.01 | 4.9% | 11.0% | TCJA $4.4B charge; ex-charge ROE 11.0% |
| 2018 | 36.6 | 9,860 | 25.27 | 13.3% | 13.3% | |
| 2019 | 36.5 | 7,897 | 21.03 | 10.0% | 10.0% | 1MDB provisions |
| 2020 | 44.6 | 8,915 | 24.74 | 11.1% | 14.4% | 1MDB settlement ~$3B litigation |
| 2021 | 59.3 | 21,151 | 59.45 | 23.0% | 23.0% | SPAC/IPO boom, PE marks |
| 2022 | 47.4 | 10,764 | 30.06 | 10.2% | 10.2% | |
| 2023 | 46.2 | 7,907 | 22.87 | 7.5% | 10.0% | Marcus/GreenSky exit, CRE & PI writedowns |
| 2024 | 53.5 | 13,525 | 40.54 | 12.7% | 12.7% | |
| 2025 | 58.3 | 16,300 | 51.32 | 15.0% | 15.0% | record GBM $41.5B |
| TTM Q3-26 | ≈74.1 | ≈21,383 | 69.57 | ≈19.3% | 9M26 ROE 20.7% annualized; Q3 incl. $450M charitable gift (−1.1pt) | |
| 10-yr avg | 11.7% | 12.9% | ex-TCJA only: 12.3% · 5-yr (2021–25): 13.7% |
For a bank, debt is raw material, not financing: deposits, repo and trading liabilities are the product, so "enterprise value" and WACC have no stable meaning, and capex/working capital cannot be separated from trading inventory. Reinvestment is set by regulatory capital (CET1 vs RWA growth), not by capex. So we value equity directly on book: justified P/B = (ROE−g)/(CoE−g), an excess-return model (book + PV of (ROE−CoE)×book), and dividend/total-payout models as cross-checks.
| Year | ROE | Book (start) | EPS | Payout (div+buyback) | Excess return | PV |
| Yr 1 (2027) | 18.0% | $373 | $67.1 | $48.4 | $27.2 | $24.6 |
| Yr 2 (2028) | 17.2% | $391 | $67.5 | $47.9 | $25.6 | $20.9 |
| Yr 3 (2029) | 16.5% | $411 | $67.8 | $47.2 | $23.8 | $17.6 |
| Yr 4 (2030) | 15.8% | $431 | $67.9 | $46.4 | $21.8 | $14.5 |
| Yr 5 (2031) | 15.0% | $453 | $67.9 | $45.3 | $19.5 | $11.7 |
| Terminal | (15.0% − 10.7%) × book $476 ÷ (10.7% − 3%) | TV $266 | $160 | |||
| Risk-free (10Y UST, ~5.2% after Sept-2026 spike) | 5.20% |
| Mature ERP | 4.40% |
| Beta (investment-bank/broker bottom-up ~1.2; GS regression ~1.3–1.4) | 1.25 |
| Cost of equity | 10.70% |
| Stable growth (≤ nominal GDP; below Rf) | 3.00% |
| Book value / tangible book per common share (9/30/26) | $372.64 / $341.43 |
| P/B · P/TBV · trailing P/E (TTM EPS ≈ $69.57) | 2.34x · 2.55x · 12.5x |
| Q3-26 net revenue / net earnings / NI to common | $18.68B / $5.29B / $5.12B |
| Q3-26 ROE / ROTE (annualized); YTD | 18.7% / 20.5%; 20.7% / 22.4% |
| Efficiency ratio Q3 / YTD; provision Q3 | 60.5% / 59.4%; $368M |
| CET1 standardized / advanced; SLR | 12.4% / 13.6%; 4.3% |
| CET1 requirement (SCB 3.4% through 9/30/27) | 11.4% → ~100bp headroom |
| Q3 capital return: buybacks (2.9M sh) + dividends | $3.00B + $1.49B = $4.49B |
| Dividend ($5.00/qtr from Q3-26) | $20/yr · 2.3% yield |
| Shares: basic 295.6M (Q3 avg); diluted ≈301M; market cap | ≈$254B |
| 52-week range | $740 – $1,154 (7/15/26) |